Next-generation drug falls shortOver £70 billion wiped off market valueRace is on for launch of oral drugDanish diabetes and obesity drug specialist Novo Nordisk (NOVO-B:CPH) gave investors a nasty surprise on Friday (20 Dec) after revealing its next generation obesity treatment CagriSema fell short of inducing significantly more weight loss than rival Mounjaro made by Eli Lilly (LLY:NYSE), sendi

Q2 guidance very weak versus consensusMicron stock plunges 15% after-hoursAnalysts say HBM story 'remains intact'Missing forecasts seldom goes down well with investors and soggy guidance is usually equally unsavoury to markets, so it comes as little surprise that Micron Technology's (MU:NASDAQ) soft outlook sparked a hefty stock reaction.Shares in the memory chipmaker plunged 15% overnight after s

2024 targets confirmedCash-flow forecast raised2025 outlook 'resilient'On an off-day for markets, with the FTSE 100 and the All-Share down 1%, facilities management group Serco (SRP) was a rare bright spot following its year-end trading update.The shares gained 8p or 6% to 147p, erasing much of their losses over the last month and indeed year-to-date. SOLID 2024 PERFORMANCEThe group, which

Stocks in London opened lower on Thursday morning following the US Federal Reserve's rate cut yesterday, as investors prepare for the Bank of England's decision this afternoon.The Fed announced another 25 basis point cut as expected, but hinted that that it will be slowing down next year in contrast with its 'jumbo' 50bp cut in September.'The market reaction was very aggressive, of course,' said S

Ongoing conflicts in Ukraine and the Middle East and calls from incoming US president Donald Trump for NATO members to increase defence spending as a percentage of national income will continue to provide a tailwind for the defence sector.AIM-quoted Cohort (CHRT:AIM) is well positioned to benefit from an increase in defence spending and at the first-half results on 11 December, the group disclosed

Premium mixer drinks company Fevertree Drinks (FEVR:AIM) has had a torrid time of late with the shares down 38% from the highs in the spring of 2024 and down two-thirds from the all-time high in December 2021.On a longer-term basis, the shares are still up 440% since listing on the AIM market in 2014, equivalent to a compound annual growth rate of 15% a year.Recent poor performance is down to a dr

What a mixed year this has turned out to be for Shares' best ideas for 2024.That our one star turn stock was an annuities and lifetime mortgage specialist, even if it was 'screamingly cheap at its current price', as we originally noted, and the supposedly exciting tech growth picks have been dull-to-dismal, might make you hark back to school days studies of Christopher Hill's The World Turned Upsi

We live in a world of seemingly endless data. Parsing and analysing this information is crucial across a range of industries and that is something GlobalData (DATA:AIM) really excels at.We think the company will make a compelling investment for the year ahead due to a renewed focus on growth. The company is committed to developing its artificial intelligence offering and has a strong balance sheet

Investment trusts have experienced challenges this year, with discounts remaining wide across various sectors and some consolidation occurring. However, certain trusts have performed well compared to both the wider market and their peer group. This article highlights the top performers across four of the Association of Investment Companies' most widely followed equity-facing sectors.GLOBALAn inves

Next year should prove a sweet one for Treatt (TET) and its shareholders. The extracts-to-ingredients supplier has the recipe for long-term growth and many of the hallmarks of a high-quality company including an unwavering focus on innovation, strong cash generation and double-digit returns on both equity and capital employed.Well-placed to profit as its end-markets recover from an unhelpful spell

The Nasdaq Composite index closed at a record high in mid-December as tech continued to drive returns ahead of the last Federal Reserve policy meeting of the year.Having recently smashed through the 20,000 mark, the index closed at 20,173.89 on 16 December, boosted by sharp jumps for Tesla (TSLA:NASDAQ) and chipmaker Broadcom (AVGO:NASDAQ).The Nasdaq 100 also closed at an all-time high 22,096.66.B

The last 10 years have been pretty rough for UK stocks but there could be some signs of life emerging as we head towards 2025.Brexit, Covid and other political and economic shocks as well as a tilt towards 'old economy' stocks and a minimal footprint in technology have combined to undermine the relevance and appeal of the UK market.The resulting underperformance has led to people consistently poin

Anyone who has walked past a building site in the UK recently might well have seen Kier (KIE) branding on it. This infrastructure and construction services outfit is actively at work on more than 400 developments across the UK. Having emerged from a difficult period with much stronger foundations, this improvement is not yet reflected in its current valuation, but we think that will change through

Stocks in London were mixed after opening higher on Wednesday, as UK inflation data increased the chances of the Bank of England holding rates steady tomorrow.The FTSE 100 index closed up just 3.91 points at 8,199.11. The FTSE 250 ended 59.13 points higher, 0.3%, at 20,601.99, and the AIM All-Share gave back 2.62 points, 0.4%, at 719.42.The Cboe UK 100 ended down 0.1% at 822.61, the Cboe UK 250 ro

Move will incur one-off cost of £1.2 millionShares fall 12% year-to-dateFull year trading expected to be in lineShares in Zotefoams (ZTF) fell over 7% to 300p in morning trading as the speciality materials maker said it will be winding down the operations of its MuCell business unit which includes its mono-material barrier packaging company ReZorce.ReZorce uses proprietary microcellular foaming t

2024/25 guidance reaffirmed$1 billion impact from Inflation Reduction ActExpected to meet 3.25 leverage target by end of 2025Embattled pharmaceutical firm Pfizer (PFE:NYSE) topped the S&P 500 index leaderboard on Tuesday (17 Dec), gaining 5% to $26.4 after confirming 2024 guidance and reaffirming 2025 forecasts in line with market expectations.The positive share price reaction to meeting consensus

Firm cites 'very challenging' tradingUnviable stores set to closeDiscounter to pass final dividendStruggling footwear retailer Shoe Zone (SHOE:AIM) has halved its current-year profit guidance and plans to pass the final dividend for the year ended 28 September 2024 after experiencing 'very challenging trading conditions' since the Budget.Combined with increased costs also stemming from the Budget,

Stocks in London were in the green on Wednesday morning, as investors prepare for eurozone inflation data and the US interest rate decision this afternoon.UK consumer price inflation and producer price inflation data came out before the London open.According to the Office for National Statistics, the consumer prices index rose by 2.6% in the 12 months to November, picking up pace on-month from a 2

UK indices were down at the close on Tuesday, as Bunzl warned deflation will have a impact on profitability.The FTSE 100 index closed down 66.85 points, 0.8%, at 8,195.20. The FTSE 250 ended 270.17 points lower, 1.3%, at 20,542.86, and the AIM All-Share gave back 7.45 points, 1.0%, at 722.04.The Cboe UK 100 ended down 0.7% at 823.10, the Cboe UK 250 fell 1.4% at 18,067.65, and the Cboe Small Compa

Sales weakness persistsDeflation to impact profitsFurther £200 million buyback announcedRenowned for its resilience, outsourcing business Bunzl (BNZL) said it expects to deliver a 'strong' year-on-year adjusted operating profit increase for the year ending 31 December 2024 in the face of an uncertain economic backdrop.So why were shares in the distribution and services business the FTSE 100's big